• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

FDA Reports Safest Blood Supply in History

September 11, 2015

Donating Blood

In the Fatalities Reported to the FDA Following Blood Collection and Transfusion: Annual Summary for Fiscal Year 2014, the FDA reported the safest blood supply in history over the last five years.

For Fiscal Years 2011 to 2014, there were 58, 65, 59 and 56 transfusion or donor related fatalities reported, respectively. The decrease in transfusion-related fatalities is largely due to improvements in donor screening, advances in testing, automated data collection and changes in plasma and whole blood policies to reduce transfusion related acute lung injury (TRALI).  Although policy changes have reduced TRALI fatalities, 41% of transfusion-related fatalities over the last 5 years are still caused by TRALI.  Transfusion associated circulatory overload had the second highest number of transfusion-related fatalities, at 22%, followed by hemolytic transfusion reactions (total 21%; non-ABO 14% and ABO 7% incompatibilities), microbial infections (8%) and anaphylactic reactions (6%).  Over the five year period, 45 total fatalities were reported post-donation.

 

 

Reference

FDA Annual Summary for Fiscal Year 2014.  Fatalities Reported to the FDA Following Blood Collection and Transfusion, August 2015.  Accessed online September 5, 2015.  http://www.fda.gov/downloads/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/UCM459461.pdf

Filed Under

  • Adverse Events (non-infectious)
  • Blood Donation
  • News
  • Quality Control and Regulatory
  • Transfusion Transmitted Infections

Recommended

  • The Genealogy of Blood Cells

  • Systematic Review Suggests Intravenous Iron Therapy Benefits Outweigh Risks

  • High-Titer Convalescent Plasma Increases Long-Term Survival for Patients with Severe COVID-19

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Directed Blood Donations Should be Limited

  • Babesia Infection Reduces Red Cell Deformability

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley